Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Anbio BiotechnologyNNNN -1.24%24 EV-to-EBIT is 61.49 as of Aug. 18, 2026, which is 68% below its 10-year median of 193.66. GuruFocus rates NNNN with a GF Score™ of 24/100. The stock has 2 warning signs investors should review. Among 471 Medical Devices & Instruments companies, Anbio Biotechnology ranks worse than 88.11% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Anbio Biotechnology's Enterprise Value for the quarter that ended in Dec. 2025 was $1,307.90 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Anbio Biotechnology's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $5.77 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anbio Biotechnology EV-to-EBIT Related Terms
Anbio Biotechnology EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Anbio Biotechnology's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Anbio Biotechnology's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anbio Biotechnology EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Anbio Biotechnology's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Anbio Biotechnology's EV-to-EBIT falls into.
Anbio Biotechnology's current Enterprise Value is $354.58 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Anbio Biotechnology's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $5.77 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anbio Biotechnology (NNNN) has a EV-to-EBIT of 61.49 as of Aug. 18, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Anbio Biotechnology and its competitors. This is 68% below median its historical median of 193.66. Over the past decade, Anbio Biotechnology's EV-to-EBIT has ranged from 58.29 to 1,117.45. According to the industry distribution chart, Anbio Biotechnology ranks #415 out of 471 companies in the Medical Devices & Instruments industry, placing it in the top 88.1%.
Is Anbio Biotechnology's EV-to-EBIT too high?
Anbio Biotechnology's current EV-to-EBIT of 61.49 is 68% below median its 10-year median of 193.66. Over the past 10 years, this metric has ranged from a low of 58.29 to a high of 1,117.45. The Medical Devices & Instruments industry median EV-to-EBIT is 19.14. Anbio Biotechnology's value of 61.49 is 221.3% above this industry median. Based on the distribution chart, Anbio Biotechnology ranks #415 out of 471 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Anbio Biotechnology has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Anbio Biotechnology's EV-to-EBIT compare to ANGO and OSUR?
According to the Medical Devices & Instruments industry distribution chart, Anbio Biotechnology ranks #415 out of 471 companies for EV-to-EBIT. This places Anbio Biotechnology in the lower half of its industry. The industry median EV-to-EBIT is 19.14. Anbio Biotechnology's value of 61.49 is 221.3% above this benchmark. Historically, Anbio Biotechnology's own EV-to-EBIT has ranged from 58.29 to 1,117.45 over the past decade. While the company's 10-year median is 193.66 vs. the industry median of 19.14, Anbio Biotechnology has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 19.14, based on 471 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Anbio Biotechnology's current EV-to-EBIT of 61.49 is 221.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Anbio Biotechnology and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 19.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Anbio Biotechnology's current EV-to-EBIT is 61.49, which is 68% below median its own 10-year median of 193.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anbio Biotechnology stock overvalued right now?
Anbio Biotechnology (NNNN) has a current EV-to-EBIT of 61.49. The current EV-to-EBIT is 61.49, which is 68% below median its 10-year median of 193.66 and 221.3% above the Medical Devices & Instruments industry median of 19.14. Anbio Biotechnology's overall GF Score™ is 24/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Anbio Biotechnology (NNNN), the current EV-to-EBIT is 61.49 as of Aug. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR).
24GF Score
Get the complete analysis for NNNN
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NNNN has been successfully added to your 
